$ICLR

Murphy Ronan Martin sold $138K of ICLR

Murphy Ronan Martin sold 841 shares of ICON PLC (ICLR) at an average of $164.29 ($162.72–$165.51, $0.14M total) across 4 trades on 2026-08-11.

Original reporting
SEC EDGAR · Murphy Ronan Martin
Published Aug 12, 2026, 9:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 12, 2026, 9:13 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ICLR
Neutral
high confidence
Mentioned
$ICLR
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ICLRNeutralLow
01

Why it matters

The newest fact is the director’s open-market sale details and post-transaction holdings; it does not include any accompanying corporate event or performance update.

02

Market read

Traders may note the insider selling activity, but there is no fundamental catalyst in the text.

03

What to watch

Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs; without additional context, signal quality is low.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-12 after trades on 2026-08-11

Background

The article is an SEC Form 4 insider transaction disclosure for ICON PLC (ICLR).

Company-level read

Ticker impact

$ICLRNeutralHigh confidence
Context

ICON PLC director Murphy Ronan Martin filed a Form 4 showing an open-market sale of 841 shares at about $164.29 average.

Expected impact

Likely minimal near-term impact; any effect would be sentiment-only and typically fades unless repeated or paired with other disclosures.

Evidence & confidence

The filing provides transaction details (size, price range, holdings) but no new guidance, contracts, litigation, or operational change for ICON PLC.

Market effects

No clear sector read-through from a single director open-market sale.

None indicated.

None indicated.

Counterpoint

Absence of a 10b5-1 plan could be interpreted as less “planned” selling, but the article provides no reason for the sale.

Key entities

  • ICON PLC

    Subject of the Form 4 insider transaction disclosure.

  • Murphy Ronan Martin

    Director who sold 841 shares across four trades on 2026-08-11.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ICLRMedAI 9/10

ICON plc: ICON Reports Second Quarter 2026 Results

ICON plc (NASDAQ: ICLR) reported Q2 2026 results. Revenue was $2,063.5 million, up 1.4% QoQ. Adjusted EBITDA was $327.2 million (15.9% of revenue). GAAP net income was $72.6 million ($0.94 diluted EPS) and adjusted net income was $198.4 million ($2.56 adjusted EPS). Net business wins were $3,120 million, backlog $23.4 billion, and it reaffirmed 2026 guidance.

$ICLRHighAI 8/10

ICON PLC (ICLR): Financial results for Q2 2026

ICON PLC (ICLR) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 ICON Reports Second Quarter 2026 Results Highlights • Quarter two revenue of $2,063.5 million, an increase of 1.4% on quarter one 2026. • Quarter two adjusted EBITDA of $327.2 million or 15.9% of revenue, an increase of 3.0% on quarter one 2026. • GAAP net income for

$ICLRMed

ICON stock surges 7% on Anthropic AI partnership for trials By Investing.com

ICON plc (NASDAQ:ICLR) shares rose about 7.8% after the company announced a multi-year partnership with Anthropic to integrate Claude AI into its Orbis clinical trial platform. ICON said the collaboration will add four production capabilities, including site intelligence and enrollment risk detection, and will roll out Claude across roles. ICON cited enrollment delays affecting up to 80% of trials.

$ICLRMed

ICON, Anthropic Sign Multi-Year Partnership Deal To Advance AI Capabilities, Stock Up In Pre-Market

ICON Public Limited Company (ICLR) said it signed a multi-year partnership with Anthropic to integrate Claude AI across the clinical trial lifecycle using ICON’s Orbis platform. ICON plans to work with Anthropic’s life sciences team and deploy Claude Code, Claude, and Claude Science. The company cited CEO Barry Balfe. In pre-market, ICLR rose to $177.69, up 5.28% on Nasdaq.